NCT06997016

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

• Status: Enrolling By Invitation
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Baylor Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are: Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain. Participants will be asked to: * Drink a pre-surgery carbohydrate drink two hours before your surgery. * Take a pre-surgery dose of Tylenol by mouth. * Take a pre-surgery dose of Gabapentin by mouth. * The surgeon will administer a local numbing medication at the surgery site by injection during the surgery. * Begin walking with assistance about 12 hours after your surgery. * Allow the research staff to collect data about your kidney function. This data will be collected on your postoperative clinic visits, which generally occur about twice weekly for one month. This information will determine your kidney health, need for hospitalization, and side effects that may occur.

Conditions

• Postoperative Pain

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	pre-operative carbohydrate drink	50 g of carbohydrate drink 2 hours before surgery
DRUG	Acetaminophen	650mg acetaminophen 30 minutes prior to surgery
DRUG	Gabapentin	300 mg gabapentin 30 minutes prior to surgery
DRUG	Bupivacaine	intraoperative local anesthetic
OTHER	Ambulation	Assisted ambulation 12 hours after surgery

Timeline

• Start date: 2025-05-05
• Primary completion: 2026-06-01
• Completion: 2027-06-01
• First posted: 2025-05-30
• Last updated: 2026-01-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study